TAVR Low Risk denied as non-formulary by Aetna?

Aetna's specific coverage criteria for tavr low risk are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issues a Non-Formulary Denial for TAVR

A non-formulary denial applied to a procedure like TAVR (transcatheter aortic valve replacement) is unusual but does occur when the insurer's benefit structure categorizes the procedure, the transcatheter valve device itself, or a bundled component under a formulary or preferred-device tier that requires additional authorization steps. Aetna may treat the implantable valve system as a medical device subject to preferred-vendor or formulary-equivalent review, meaning that unless the specific device or facility is on a preferred list, coverage is initially declined.

This denial is appealable on several grounds: (1) TAVR is FDA-approved for low-surgical-risk patients and is guideline-endorsed by leading cardiovascular professional societies; (2) non-formulary exclusions typically cannot override coverage for medically necessary, FDA-cleared procedures under ACA-compliant and ERISA plans; and (3) if no "preferred" TAVR option exists that is clinically appropriate for your anatomy, a medical-exception pathway is almost always available.

## Federal Appeal Rights

Under ACA §2719 and ERISA §503, you are entitled to a full-and-fair internal review followed by independent external review. The external review window is typically within four months of the final internal denial — verify the exact date from your denial letter. Expedited review is available when delay poses a health risk.

## Appeal Process and Timeline

1. Clarify the basis: Determine from Aetna whether the denial is device-specific (a particular valve brand), facility-specific, or a procedural formulary issue. 2. File a Level 1 internal appeal including a medical-necessity and medical-exception argument. 3. Obtain a medical-exception letter from your structural heart team explaining why the specific device and facility are required for your anatomical and clinical situation. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Device-specific clinical rationale: A letter from your interventional cardiologist explaining why the selected TAVR system (size, design features) is required by your specific anatomy, based on cardiac CT measurements — without citing specific numeric thresholds that could be outdated.
• Facility qualification: Documentation that the performing center meets criteria for structural heart programs (e.g., participation in national valve registries, volume standards recognized by ACC/STS).
• Medical-necessity letter: A comprehensive letter from your structural heart team documenting symptom severity, surgical risk classification, and why TAVR is the appropriate intervention.
• Benefit plan language: Obtain your Summary Plan Description and identify any formulary-exception process described there.

## Criteria-Mapping Structure

For a non-formulary appeal, map the exception criteria Aetna requires against the clinical facts: list each condition for a medical exception (e.g., no clinically appropriate preferred alternative exists, the preferred alternative is contraindicated per the prescribing team's clinical judgment) and show, line by line, how the record satisfies each one. Attach the relevant clinical notes, imaging reports, and the prescriber's letter as labeled exhibits.